{"success":true,"data":{"pressRelease":{"id":"164027","rtpr_id":"nGNX8FlSzt-20261008","ticker":"BSEM","exchange":"NASDAQ","all_tickers":["BSEM"],"title":"BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options","author":"Globe Newswire","published_at":"2026-10-08T11:00:00.920Z","article_body":"POMPANO BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies,\nInc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading\nregenerative medicine company focused on the development, manufacturing, and\ncommercialization of perinatal tissue allograft products, today announced its\nChair and Chief Executive Officer, Jason Matuszewski, and Chief Operating\nOfficer, Andrew Van Vurst, each exercised a portion of their outstanding\noptions to purchase 250,000 shares of BioStem common stock at an exercise\nprice of $2.00 per share, for a total of 500,000 shares and an aggregate\npurchase price of approximately $1 million.\n\n“This is an exciting and important time for the Company,” said Mr.\nMatuszewski. “Hospitals are increasingly seeking wound care and surgical\nsolutions that are clinically supported, reliably supplied, and economically\nsensible and we believe we have built one of the broadest perinatal allograft\nportfolios in the industry to meet exactly that need. Exercising these options\nreflects my continued confidence in the Company, our team and the potential\nfor our technology. I believe this capital will support broader sales\ncoverage, expanded hospital formulary coverage, and the inventory needed to\nsupport new accounts.  I am proud to reiterate my support and remain highly\ncommitted to creating long-term value for fellow shareholders.”\n\n\"Our role on the operations side is to help ensure that growth does not\noutpace our ability to deliver, and we've built BioStem with that objective in\nmind,\" said Mr. Van Vurst. \"I see the progress every day, in our production,\nquality processes, and supply planning. We believe the additional capital will\nhelp support the inventory and infrastructure needed to serve new hospital\naccounts, and we remain focused on consistent execution for the customers and\npatients who rely on our products.”\n\nForward-Looking Statements:\n\nCertain statements in this press release may be considered “forward-looking\nstatements” within the meaning of the Private Securities Litigation Reform\nAct of 1995. These forward-looking statements relate to expectations or\nforecasts of future events. Forward-looking statements may be identified using\nwords such as “intend,” “seek,” “target,” “anticipate,”\n“believe,” “expect,” “estimate”, “plan,” “outlook,”\n“project” and other similar expressions that predict or indicate future\nevents or trends or that are not statements of historical matters.\nForward-looking statements in this press release include, without limitation,\nstatements regarding the application of new capital received by the Company,\nthe Company’s ability to meet market needs and the Company’s growth\nprospects.\n\nForward-looking statements are based on current expectations and are subject\nto known and unknown risks and uncertainties which could cause actual results\nor outcomes to differ materially from the expectations expressed or implied by\nsuch forward-looking statements. These factors include, but are not limited\nto: the Company’s ability to maintain compliance with Nasdaq’s continued\nlisting standards; the Company’s ability to obtain financing on terms\nacceptable to it, or at all; the impact of any changes in applicable laws or\nregulations; the Company’s accounts receivable collection risk and\nconcentration; the Company’s ability to maintain production of its products\nin sufficient quantities to meet demand; and the possibility that the Company\nmay be adversely affected by other general economic, business, and/or\ncompetitive factors. There may be additional risks which the Company is\npresently unaware of or that the Company currently believes are immaterial\nthat could also cause actual results to differ from those contained in the\nforward-looking statements. You are cautioned not to place undue reliance upon\nany forward-looking statements, which speak only as of the date made. The\nCompany undertakes no duty to update or revise the forward-looking statements,\nwhether as a result of new information, future events or otherwise, except as\nrequired by law.\n\nAbout BioStem Technologies, Inc. (Nasdaq: BSEM): BioStem Technologies, Inc. is\na publicly traded, biomedical innovator, focused on developing, manufacturing\nand commercializing advanced allograft solutions derived from perinatal\ntissue. The company leverages its industry-leading proprietary BioRetain®,\nCryoTek® and SteriTek® processing technologies, designed to optimize the\npreservation of the natural properties of these tissues, supporting their use\nin clinical settings. Its allografts are used by clinicians across a wide\nrange of specialties. With a growing portfolio of products, expanding clinical\nresearch initiatives, and a national commercial footprint, BioStem is\ncommitted to advancing innovation in regenerative medicine.\n\nBioStem Technologies’ quality management system and standard operating\nprocedures have been reviewed and accredited by the Association for Advancing\nTissue and Biologics (“AATB”). These systems and procedures are\nestablished in compliance with current Good Tissue Practices (“cGTP”) and\ncurrent Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of\nquality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™\nproduct lines.\n\nJoin BioStem’s Distribution List & Social Media:\nTo follow the latest developments at BioStem, sign up for the Company’s\nemail distribution list HERE\n(https://www.globenewswire.com/Tracker?data=FxJ6CV1rTYrfwchWqPhz3LLORaDvnmlwxCoXT10SlwCZjOPKnMDcqGj8FOLlIYK6efd0fMHk-iKDq_nne7a90S0dMCpi8Glf84DRZOfMnKv75wMGSCKrgZUHD19EIYkGl1_-PkB4tpXdqDMYna-98R2yPTzrtQScfY0ZgIfHpECPXeftiBi-9YdcfMybAivqMMbX9vxkT7PJzYuXGxQ4tm7s-iwEhHK2cdS-fiu_vPU4ABCsBOC2LnIC092L8zePKXAo6mAUTSneVyx1zhw-OQgjWSEWozoYfll9c5v4UT7ymkpQw_xtx-oB39kGnNnWSGsGSZYQYu-TRrgvkwg5cEXOd1tGZKYojFUiQs_VtHETpoxbjIezd99U2MHf8b6J6TPTX_ZeDyoXyCo_qRjiTFGuubZgbG19brnFja4fzMtz2p6zjegAFaNg2yngR0IMo_3OydHfvb_8_ioFJbVCzYXgAw1vL48lReqHrGn4s2vdX6zrEi7DOLWgAGq9tRsXhwmxgl-3sV9av1F5piFuwD8k2Pb8sUzEJ10vGEgx8EzSQJVMF5u8zKFcsnv4TwORlsgAiPTGr5uV9-T64wPCnGxOmYRUeRPGej8ZofJ1lkPNZ49FH7NCqd31kPAFu6huq2sUKPuNmVBktzamyyMrqEZyl8lInB7ryrsIxtS0fO3oTWSnpSOm5ICIDIgn_8I87zLPWGgkn-kZ_M5F0OlDNd6iSMDEs6dclu7Z5XXWSJs5gMg3rQ8SgM5wYx7gHQocZZCS9en6ixs_OV6g-1BMJZc5Ws_uwXsLgaosQTPaO_t0-jxbHwZuIXftNgxsxUyVt-p2cSmzLdQHVICMfi7URKr_wqp6zK3CRJczI9kblkF0V4B8SG2qCqI0WgYyxqn2TckxhVpR8WrQUh5vnXnSm__R9mXWoki-2iQihB2hdy5IWuqBnPtFyvUQW5Ckvbv2Kx_w9iGu_r6qQ9XGQT7d9n-wCR1gdP_F5n4SaXtdif-XflUJTfLnCCxWIsvLuMch7sjlqDNlN5qmtrkn-jQwXMFRvneiHH8AgD1AixgRquFyasNcWysc5-6Hno4PfcPVQMuaq8_IV6z98OhPfa-WFmExmegP-JqSC3EDDfzg0AaKpz4hvrhuwh_ShYcrF7Qz_Dp0yTPBSymJ8UU82xFFdsH3YiyEAqJLjzDDqT7MqqKgEd__T5GpKo6TGNOMWYYtebkF9emImDip_Il3Nk6bVQte_7NTLB1GpstUgln8PFDdXgbAF2YQFFwpBy78_lU6XdT2NHt6l0xmLcRx1-jsUYj2aUgGcuz7OR9yMj-6d520OJbCLISaf4zEdRKaD2UuVr7ETETTcbt3kIOYmWo0A7vVPq1B1nVrXofqOaqzrVg=),\nand follow us on X\n(https://www.globenewswire.com/Tracker?data=lbtBQW4IUfIlZWrxoDBYOi5GXWxVB_O2KGTV3Fk6LIjlg8hWY6Myned_IH9P_t5ls2_M4BrlaKTIFzL2_tpQBWNktB_CEesGrCdfBahUdZxZJy8YZEjCzRgwz00wfTiVnbaYVwqPqaXiuoYSxg5Oqsqq7GEaa5RnjlcfxPWVGOlTMOHCqrCOcNnzqkcOQW_ubg9QCRMUIHsxPk4Y32suHO9lO7atGTp9EQLtrKKmMIcXzAj5Di5oiJh8WHloJe1Bdf7V7rk8I_ZNytRPxS0jfqzw_E3VtWv1sG76lquRJRSCORL2KXBGLHrIOaDKifwB4v3XHIK4SGsPXwjQZl8dujY_qJ8O2eIJYhtH585K47xw14nojMNWBXNz-MaYFzB6nRV8gOXngfn2AgFp6uIIcUJCPV6PxNFPfjT3NVAwi4zb3Bw1yheeszeurHjgjXCk1cG4nDQZ-iIcqwe4IK9wmzzVtMyKjzkizN6VPHPyuVKzO9I_5ZL9KMB_3HAehpJRfTe2UUIW5sabcvk63zHVkNxun2Ru-qfAyCveOhCLALu38KgfazGRkLWbD91p8hl8styomeMPBGS3zeSbR5bWgxlgobCNneTZaTPVtf4IJIqFynL7EASzl30Ruu9TEmMfA6C__DXd4PLCrSy0M4KxVb0U97chduL6EbhycfK4rvr4To1wGi5NUqxuRx5CsXDipxxu1P9-EkNmauRbUUsH25v8Oqjvh7eDTjPsCTH7_RW611t1clnBXR-zkD1JKAwEYF0f63ezbpzmH_iXn7CbdPf0_g9Lk8HBFTCCiJpPuJGie70RXvg8nL-f_VblLlnjZ9WacVuYSSgKPnuIKz0EzZElaEJVfFVSIRRpcq9NU1pK98MPlxbj11hZzpzCpy6XX5QwGLJPjkYVKmJjlaVahZsOoXYLZDpkIuzofT_Y5zPYkYUmO_dha5q6KWluNSEUmWdieyMBJjZE7Cs7YMFuRW8gUb3TKyUCAG6xUtg_cspAkSN4cVBA6nYNGUukAgz5V9fIN5tKNBA95AA-Ti3U43eEr9xkwscTFF3PHuJOuvnyhGG9ZphCsJd3OOIrDyXRgtefcK_UkbrsWUg16X7dPrwmiL940LuVII8BuqQNuS40lD0UjIIP3szahCnJAPrCA7_UkkNWGrVoTSUmg7qJu2B7BlR4ooTxEEafxqaoOnAYNSnrqkve8OE-4V5ysea4O9KgbifMP1QOdIKxpigSygk321oVo3NRVayBSD1Z3ieA4Y4NvqnB-vpFZxawy_QD1t0w3CxnW3EMCAIODjOwBlnG77Du10bKKDkbE-DmpPxJ5aidqF3lOohnyXnCs9UFCs2uEz4ibsYgJ81CTSTqjYDpk5M5ApF8GtB9mPDr0Lyy8UAIbIpKATXS0YvAC_uDa-Xgcgxcy0DjvLPkxci3ZdkyjSKT6s5xY1W5h5kwiETD25beB6S06DA2vOAoPtBMIn6PNQLPPlZIEsEUV0YVf5CLoUdbpzlthND8a6JBZtQn7ePCDNmdPJ-MUhmeiRZ6yxhfmOgla7Rx0CxQMlRsmpb7PjOK-xmeia_KP3gyBPw9bn4erpKzJyJlU6oqf0BlFRQs8vA5H5PVNsMKG5Woobol4pkX39OXeohX7Qcf1xYXJiiFPDdzjrPCSNCF1Fosdb2RW8JHXO1y2NS2AQ86pLg7o0a7Jf4W-qbmPEuoc29MONND3C-QXE4JFo9oXdsfvjoAPGo8YUN59GQKw7Lh_7hz9G1YcDDf9SRmXozc6vw=)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=frcOwsY3S0QHUhBsaHJWKrCJxOKymB9FGdeR6sJHsY4V5xeQkql-qj2kEyjjgTyOaWxla0rplnVifQar8HuJ_2YDfnw73hwq9iyeSDbmRI_wm40TjUEDq9yms0-hDphgwMzod6SIgVe8MuaJ12PqosLjcR2rHyCtQ4r-oUo6-tnNQyb2476lX5l4hL4_2AVGktLfkWIHZQzrZYvRN2JypqyHKOek_WNVVtlcwZB2ERFdMvNH9FKF_SJENpA49PNemYaDqpEGyJa4Zqr8WO0gCKkxVwoXnEivWsIHC50CfX9syLY6tIalBE4DJgrqSNxuUuUY_0GolVOrpylTmx9IQySc4EnA76bAlarlABUaFxkHAcsS5kQ1pxZmFgZULXjfJPLdOnJAjKJnayGqNZHB1lXlFI0iIpqfxn36uE0v-Nyrl3jjzB8V5WqBf-qdnk1l4oGbB2XIRSO2_5Hohoh94lb69i_uj5wVTyX67P21Oq1AmeALBKXt8A7NgtXQvxGGhZ5eqLTKjRbR0xeA88D0Ipk39slKbr6g3cNEHE-Bt5L2xJ4IyTshgZ74OkFz2C3fmVX6yCBJW3MzVjtIu6XY5aJ4pnUk40h2Y-Byhv7aCpX8xVIF5PNOXLwyYUEJTa29A0nELFMKchzRE9h81gbCzup1TfpcaxaEZgtFqikZ3BeWyHmSX8Gi8SP94_6-DLBJ8xYdichAU4sjp_rkymvCC0gaRpJJZofBIhy8WnvEi2sxiOiq0xXWY8X-ktMyUh1bzMQf-gnNEHEtPI4sL4iTFP5i6MC_9S8MlyDyr7Pbq2ib1EPtP9FTGS86ZLCbKzy6oSjOPpDcJmf0GjpnnUD25ip4UGwUoiWYzsiB34YYIF10Nmj61h1C5vYnkpJvtb5cNO3hgYAJIHRTbEWqhSArFGpDM2BlMaL-44iqA39h0Z2iJOXC6z44hQZo7_09pcHpijP1cJOwLzyPqKjlSvOGsWFXW_nhseqB83BXSaUjXy_m3sK6EPoVEpKi18wYwkb4m9JQPEa70X-A9kX06POQRJrTjoMHpkqesfE5foO4FyUZsi8Sp_pHwfeK-feK_B3FOEkjtA0dA5MFinIvX4R_97m43Z3C8pBjKHFuMecoiYIEd3SCpbLvbpsV0r5E_WTXb_hIcDLNvqpxIV1YZ6p75behgG1DmWkhS1mDHwKQ49_AxMuH4lltQLvZGWiaEZ8J3meZLyta9I2gXoidQMC57eDCyV63TjqaqkFX1PChuZy8fc-eEx2xyc7OBS-JmkuJEnIkbQbHKphO1JDPDvI0K8pqMu41gIivU31tRWc3PPdeQ7WmQZVs5OKzvyvz8kpHXnKlo2ODj0aOUhvl5fKfUdCj_cJVEbKSM5-ZBQGZsO0RUPSZe4gzV308J2-lXgMpn7m40MTbvU1o7UC4MKgFv9UsU-K8Ej-l0aQpuvuhNMQkNQ6yLlNcvcEfg9gOvTCOBMpRImzMG_LkGCtwUTgRpsnJvT7aq9RM9XpgEX1SsjsVKhcyw_dd5FlwfsmQzCGy2ntv5_GdZCUMvp--MMryi5q3AHcKDNCvYQMEl2xdrvZhrQUg-FgJmSxMCEnv-__oREimQgRVVAYPYJ3QXd0Amhr5sPTu-qv31ir_7L5-mSdtXOS1E0A0p8MBkk9zhKBre1zQNj5vIkCmDlISIV_mdgSNNVrfZ0R1ErTfgmYVEgXzGPkP8QzLDi3Hx6QhLLjocLjzEWjB6ckrNM1cbOj1lxBKGTq-huilffIzROqRr7w=).\n\nContact BioStem: \nWebsite: www.biostemtechnologies.com\nE-Mail: pr@biostemtech.com\nX: @BSEM_Tech\nFacebook: BioStemTechnologies\n(https://www.globenewswire.com/Tracker?data=7M7TVZEWTvHq6iUEr14Iqt7Dt2x0REKetYZfDdMkXAkItbxFC7sTKgbq5TXNT_Yvp88m_34a_BIyn4UU_Fb7UKkC1EfuCYsjmmYHqJVlHPswgxwO8iOsno-XWlgctoVH)\nPhone: 954-380-8342\n\nInvestor Relations: \nPhilip Trip Taylor, Gilmartin Group\nir@biostemtech.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/da0ea21a-fd6e-425a-a8f2-6f69dc2b4612)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8FlSzt-20261008","title":"BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options","author":"Globe Newswire","ticker":"BSEM","created":"2026-10-08T11:00:00.920Z","tickers":["BSEM"],"exchange":"NASDAQ","article_body":"POMPANO BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies,\nInc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading\nregenerative medicine company focused on the development, manufacturing, and\ncommercialization of perinatal tissue allograft products, today announced its\nChair and Chief Executive Officer, Jason Matuszewski, and Chief Operating\nOfficer, Andrew Van Vurst, each exercised a portion of their outstanding\noptions to purchase 250,000 shares of BioStem common stock at an exercise\nprice of $2.00 per share, for a total of 500,000 shares and an aggregate\npurchase price of approximately $1 million.\n\n“This is an exciting and important time for the Company,” said Mr.\nMatuszewski. “Hospitals are increasingly seeking wound care and surgical\nsolutions that are clinically supported, reliably supplied, and economically\nsensible and we believe we have built one of the broadest perinatal allograft\nportfolios in the industry to meet exactly that need. Exercising these options\nreflects my continued confidence in the Company, our team and the potential\nfor our technology. I believe this capital will support broader sales\ncoverage, expanded hospital formulary coverage, and the inventory needed to\nsupport new accounts.  I am proud to reiterate my support and remain highly\ncommitted to creating long-term value for fellow shareholders.”\n\n\"Our role on the operations side is to help ensure that growth does not\noutpace our ability to deliver, and we've built BioStem with that objective in\nmind,\" said Mr. Van Vurst. \"I see the progress every day, in our production,\nquality processes, and supply planning. We believe the additional capital will\nhelp support the inventory and infrastructure needed to serve new hospital\naccounts, and we remain focused on consistent execution for the customers and\npatients who rely on our products.”\n\nForward-Looking Statements:\n\nCertain statements in this press release may be considered “forward-looking\nstatements” within the meaning of the Private Securities Litigation Reform\nAct of 1995. These forward-looking statements relate to expectations or\nforecasts of future events. Forward-looking statements may be identified using\nwords such as “intend,” “seek,” “target,” “anticipate,”\n“believe,” “expect,” “estimate”, “plan,” “outlook,”\n“project” and other similar expressions that predict or indicate future\nevents or trends or that are not statements of historical matters.\nForward-looking statements in this press release include, without limitation,\nstatements regarding the application of new capital received by the Company,\nthe Company’s ability to meet market needs and the Company’s growth\nprospects.\n\nForward-looking statements are based on current expectations and are subject\nto known and unknown risks and uncertainties which could cause actual results\nor outcomes to differ materially from the expectations expressed or implied by\nsuch forward-looking statements. These factors include, but are not limited\nto: the Company’s ability to maintain compliance with Nasdaq’s continued\nlisting standards; the Company’s ability to obtain financing on terms\nacceptable to it, or at all; the impact of any changes in applicable laws or\nregulations; the Company’s accounts receivable collection risk and\nconcentration; the Company’s ability to maintain production of its products\nin sufficient quantities to meet demand; and the possibility that the Company\nmay be adversely affected by other general economic, business, and/or\ncompetitive factors. There may be additional risks which the Company is\npresently unaware of or that the Company currently believes are immaterial\nthat could also cause actual results to differ from those contained in the\nforward-looking statements. You are cautioned not to place undue reliance upon\nany forward-looking statements, which speak only as of the date made. The\nCompany undertakes no duty to update or revise the forward-looking statements,\nwhether as a result of new information, future events or otherwise, except as\nrequired by law.\n\nAbout BioStem Technologies, Inc. (Nasdaq: BSEM): BioStem Technologies, Inc. is\na publicly traded, biomedical innovator, focused on developing, manufacturing\nand commercializing advanced allograft solutions derived from perinatal\ntissue. The company leverages its industry-leading proprietary BioRetain®,\nCryoTek® and SteriTek® processing technologies, designed to optimize the\npreservation of the natural properties of these tissues, supporting their use\nin clinical settings. Its allografts are used by clinicians across a wide\nrange of specialties. With a growing portfolio of products, expanding clinical\nresearch initiatives, and a national commercial footprint, BioStem is\ncommitted to advancing innovation in regenerative medicine.\n\nBioStem Technologies’ quality management system and standard operating\nprocedures have been reviewed and accredited by the Association for Advancing\nTissue and Biologics (“AATB”). These systems and procedures are\nestablished in compliance with current Good Tissue Practices (“cGTP”) and\ncurrent Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of\nquality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™\nproduct lines.\n\nJoin BioStem’s Distribution List & Social Media:\nTo follow the latest developments at BioStem, sign up for the Company’s\nemail distribution list HERE\n(https://www.globenewswire.com/Tracker?data=FxJ6CV1rTYrfwchWqPhz3LLORaDvnmlwxCoXT10SlwCZjOPKnMDcqGj8FOLlIYK6efd0fMHk-iKDq_nne7a90S0dMCpi8Glf84DRZOfMnKv75wMGSCKrgZUHD19EIYkGl1_-PkB4tpXdqDMYna-98R2yPTzrtQScfY0ZgIfHpECPXeftiBi-9YdcfMybAivqMMbX9vxkT7PJzYuXGxQ4tm7s-iwEhHK2cdS-fiu_vPU4ABCsBOC2LnIC092L8zePKXAo6mAUTSneVyx1zhw-OQgjWSEWozoYfll9c5v4UT7ymkpQw_xtx-oB39kGnNnWSGsGSZYQYu-TRrgvkwg5cEXOd1tGZKYojFUiQs_VtHETpoxbjIezd99U2MHf8b6J6TPTX_ZeDyoXyCo_qRjiTFGuubZgbG19brnFja4fzMtz2p6zjegAFaNg2yngR0IMo_3OydHfvb_8_ioFJbVCzYXgAw1vL48lReqHrGn4s2vdX6zrEi7DOLWgAGq9tRsXhwmxgl-3sV9av1F5piFuwD8k2Pb8sUzEJ10vGEgx8EzSQJVMF5u8zKFcsnv4TwORlsgAiPTGr5uV9-T64wPCnGxOmYRUeRPGej8ZofJ1lkPNZ49FH7NCqd31kPAFu6huq2sUKPuNmVBktzamyyMrqEZyl8lInB7ryrsIxtS0fO3oTWSnpSOm5ICIDIgn_8I87zLPWGgkn-kZ_M5F0OlDNd6iSMDEs6dclu7Z5XXWSJs5gMg3rQ8SgM5wYx7gHQocZZCS9en6ixs_OV6g-1BMJZc5Ws_uwXsLgaosQTPaO_t0-jxbHwZuIXftNgxsxUyVt-p2cSmzLdQHVICMfi7URKr_wqp6zK3CRJczI9kblkF0V4B8SG2qCqI0WgYyxqn2TckxhVpR8WrQUh5vnXnSm__R9mXWoki-2iQihB2hdy5IWuqBnPtFyvUQW5Ckvbv2Kx_w9iGu_r6qQ9XGQT7d9n-wCR1gdP_F5n4SaXtdif-XflUJTfLnCCxWIsvLuMch7sjlqDNlN5qmtrkn-jQwXMFRvneiHH8AgD1AixgRquFyasNcWysc5-6Hno4PfcPVQMuaq8_IV6z98OhPfa-WFmExmegP-JqSC3EDDfzg0AaKpz4hvrhuwh_ShYcrF7Qz_Dp0yTPBSymJ8UU82xFFdsH3YiyEAqJLjzDDqT7MqqKgEd__T5GpKo6TGNOMWYYtebkF9emImDip_Il3Nk6bVQte_7NTLB1GpstUgln8PFDdXgbAF2YQFFwpBy78_lU6XdT2NHt6l0xmLcRx1-jsUYj2aUgGcuz7OR9yMj-6d520OJbCLISaf4zEdRKaD2UuVr7ETETTcbt3kIOYmWo0A7vVPq1B1nVrXofqOaqzrVg=),\nand follow us on X\n(https://www.globenewswire.com/Tracker?data=lbtBQW4IUfIlZWrxoDBYOi5GXWxVB_O2KGTV3Fk6LIjlg8hWY6Myned_IH9P_t5ls2_M4BrlaKTIFzL2_tpQBWNktB_CEesGrCdfBahUdZxZJy8YZEjCzRgwz00wfTiVnbaYVwqPqaXiuoYSxg5Oqsqq7GEaa5RnjlcfxPWVGOlTMOHCqrCOcNnzqkcOQW_ubg9QCRMUIHsxPk4Y32suHO9lO7atGTp9EQLtrKKmMIcXzAj5Di5oiJh8WHloJe1Bdf7V7rk8I_ZNytRPxS0jfqzw_E3VtWv1sG76lquRJRSCORL2KXBGLHrIOaDKifwB4v3XHIK4SGsPXwjQZl8dujY_qJ8O2eIJYhtH585K47xw14nojMNWBXNz-MaYFzB6nRV8gOXngfn2AgFp6uIIcUJCPV6PxNFPfjT3NVAwi4zb3Bw1yheeszeurHjgjXCk1cG4nDQZ-iIcqwe4IK9wmzzVtMyKjzkizN6VPHPyuVKzO9I_5ZL9KMB_3HAehpJRfTe2UUIW5sabcvk63zHVkNxun2Ru-qfAyCveOhCLALu38KgfazGRkLWbD91p8hl8styomeMPBGS3zeSbR5bWgxlgobCNneTZaTPVtf4IJIqFynL7EASzl30Ruu9TEmMfA6C__DXd4PLCrSy0M4KxVb0U97chduL6EbhycfK4rvr4To1wGi5NUqxuRx5CsXDipxxu1P9-EkNmauRbUUsH25v8Oqjvh7eDTjPsCTH7_RW611t1clnBXR-zkD1JKAwEYF0f63ezbpzmH_iXn7CbdPf0_g9Lk8HBFTCCiJpPuJGie70RXvg8nL-f_VblLlnjZ9WacVuYSSgKPnuIKz0EzZElaEJVfFVSIRRpcq9NU1pK98MPlxbj11hZzpzCpy6XX5QwGLJPjkYVKmJjlaVahZsOoXYLZDpkIuzofT_Y5zPYkYUmO_dha5q6KWluNSEUmWdieyMBJjZE7Cs7YMFuRW8gUb3TKyUCAG6xUtg_cspAkSN4cVBA6nYNGUukAgz5V9fIN5tKNBA95AA-Ti3U43eEr9xkwscTFF3PHuJOuvnyhGG9ZphCsJd3OOIrDyXRgtefcK_UkbrsWUg16X7dPrwmiL940LuVII8BuqQNuS40lD0UjIIP3szahCnJAPrCA7_UkkNWGrVoTSUmg7qJu2B7BlR4ooTxEEafxqaoOnAYNSnrqkve8OE-4V5ysea4O9KgbifMP1QOdIKxpigSygk321oVo3NRVayBSD1Z3ieA4Y4NvqnB-vpFZxawy_QD1t0w3CxnW3EMCAIODjOwBlnG77Du10bKKDkbE-DmpPxJ5aidqF3lOohnyXnCs9UFCs2uEz4ibsYgJ81CTSTqjYDpk5M5ApF8GtB9mPDr0Lyy8UAIbIpKATXS0YvAC_uDa-Xgcgxcy0DjvLPkxci3ZdkyjSKT6s5xY1W5h5kwiETD25beB6S06DA2vOAoPtBMIn6PNQLPPlZIEsEUV0YVf5CLoUdbpzlthND8a6JBZtQn7ePCDNmdPJ-MUhmeiRZ6yxhfmOgla7Rx0CxQMlRsmpb7PjOK-xmeia_KP3gyBPw9bn4erpKzJyJlU6oqf0BlFRQs8vA5H5PVNsMKG5Woobol4pkX39OXeohX7Qcf1xYXJiiFPDdzjrPCSNCF1Fosdb2RW8JHXO1y2NS2AQ86pLg7o0a7Jf4W-qbmPEuoc29MONND3C-QXE4JFo9oXdsfvjoAPGo8YUN59GQKw7Lh_7hz9G1YcDDf9SRmXozc6vw=)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=frcOwsY3S0QHUhBsaHJWKrCJxOKymB9FGdeR6sJHsY4V5xeQkql-qj2kEyjjgTyOaWxla0rplnVifQar8HuJ_2YDfnw73hwq9iyeSDbmRI_wm40TjUEDq9yms0-hDphgwMzod6SIgVe8MuaJ12PqosLjcR2rHyCtQ4r-oUo6-tnNQyb2476lX5l4hL4_2AVGktLfkWIHZQzrZYvRN2JypqyHKOek_WNVVtlcwZB2ERFdMvNH9FKF_SJENpA49PNemYaDqpEGyJa4Zqr8WO0gCKkxVwoXnEivWsIHC50CfX9syLY6tIalBE4DJgrqSNxuUuUY_0GolVOrpylTmx9IQySc4EnA76bAlarlABUaFxkHAcsS5kQ1pxZmFgZULXjfJPLdOnJAjKJnayGqNZHB1lXlFI0iIpqfxn36uE0v-Nyrl3jjzB8V5WqBf-qdnk1l4oGbB2XIRSO2_5Hohoh94lb69i_uj5wVTyX67P21Oq1AmeALBKXt8A7NgtXQvxGGhZ5eqLTKjRbR0xeA88D0Ipk39slKbr6g3cNEHE-Bt5L2xJ4IyTshgZ74OkFz2C3fmVX6yCBJW3MzVjtIu6XY5aJ4pnUk40h2Y-Byhv7aCpX8xVIF5PNOXLwyYUEJTa29A0nELFMKchzRE9h81gbCzup1TfpcaxaEZgtFqikZ3BeWyHmSX8Gi8SP94_6-DLBJ8xYdichAU4sjp_rkymvCC0gaRpJJZofBIhy8WnvEi2sxiOiq0xXWY8X-ktMyUh1bzMQf-gnNEHEtPI4sL4iTFP5i6MC_9S8MlyDyr7Pbq2ib1EPtP9FTGS86ZLCbKzy6oSjOPpDcJmf0GjpnnUD25ip4UGwUoiWYzsiB34YYIF10Nmj61h1C5vYnkpJvtb5cNO3hgYAJIHRTbEWqhSArFGpDM2BlMaL-44iqA39h0Z2iJOXC6z44hQZo7_09pcHpijP1cJOwLzyPqKjlSvOGsWFXW_nhseqB83BXSaUjXy_m3sK6EPoVEpKi18wYwkb4m9JQPEa70X-A9kX06POQRJrTjoMHpkqesfE5foO4FyUZsi8Sp_pHwfeK-feK_B3FOEkjtA0dA5MFinIvX4R_97m43Z3C8pBjKHFuMecoiYIEd3SCpbLvbpsV0r5E_WTXb_hIcDLNvqpxIV1YZ6p75behgG1DmWkhS1mDHwKQ49_AxMuH4lltQLvZGWiaEZ8J3meZLyta9I2gXoidQMC57eDCyV63TjqaqkFX1PChuZy8fc-eEx2xyc7OBS-JmkuJEnIkbQbHKphO1JDPDvI0K8pqMu41gIivU31tRWc3PPdeQ7WmQZVs5OKzvyvz8kpHXnKlo2ODj0aOUhvl5fKfUdCj_cJVEbKSM5-ZBQGZsO0RUPSZe4gzV308J2-lXgMpn7m40MTbvU1o7UC4MKgFv9UsU-K8Ej-l0aQpuvuhNMQkNQ6yLlNcvcEfg9gOvTCOBMpRImzMG_LkGCtwUTgRpsnJvT7aq9RM9XpgEX1SsjsVKhcyw_dd5FlwfsmQzCGy2ntv5_GdZCUMvp--MMryi5q3AHcKDNCvYQMEl2xdrvZhrQUg-FgJmSxMCEnv-__oREimQgRVVAYPYJ3QXd0Amhr5sPTu-qv31ir_7L5-mSdtXOS1E0A0p8MBkk9zhKBre1zQNj5vIkCmDlISIV_mdgSNNVrfZ0R1ErTfgmYVEgXzGPkP8QzLDi3Hx6QhLLjocLjzEWjB6ckrNM1cbOj1lxBKGTq-huilffIzROqRr7w=).\n\nContact BioStem: \nWebsite: www.biostemtechnologies.com\nE-Mail: pr@biostemtech.com\nX: @BSEM_Tech\nFacebook: BioStemTechnologies\n(https://www.globenewswire.com/Tracker?data=7M7TVZEWTvHq6iUEr14Iqt7Dt2x0REKetYZfDdMkXAkItbxFC7sTKgbq5TXNT_Yvp88m_34a_BIyn4UU_Fb7UKkC1EfuCYsjmmYHqJVlHPswgxwO8iOsno-XWlgctoVH)\nPhone: 954-380-8342\n\nInvestor Relations: \nPhilip Trip Taylor, Gilmartin Group\nir@biostemtech.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/da0ea21a-fd6e-425a-a8f2-6f69dc2b4612)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-08T11:00:00.98867713Z","server_sent_at_ms":1791457200988},"received_at":"2026-10-08T11:00:01.052Z","source_url":null},"analysis":{"id":"152462","press_release_id":"164027","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["forward-looking statements flag Nasdaq continued-listing compliance and financing risk","accounts receivable collection risk and concentration cited as risk factors"],"eventType":"insider_transaction","narrative":"BioStem Technologies' Chair and CEO Jason Matuszewski and COO Andrew Van Vurst each exercised options for 250,000 shares at $2.00 per share, paying approximately $1 million in aggregate cash to the company.\n\nBoth executives framed the exercises as a vote of confidence, with the capital earmarked to support sales coverage, hospital formulary expansion, and inventory for new accounts.\n\nOption exercises by insiders inject cash into the company but also add 500,000 shares of dilution; the modest size caps the market significance of the event.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Insider confidence signal: CEO and COO put $1M of their own cash into BSEM via option exercises at $2.00."},"keyFigures":{"customDimensions":{"shares_exercised_each":250000,"shares_exercised_total":500000,"aggregate_purchase_price":"$1 million","exercise_price_per_share":"$2.00"}},"quotedText":"Exercising these options reflects my continued confidence in the Company, our team and the potential for our technology.","namedEntities":{"people":[{"name":"Jason Matuszewski","role":"Chair and CEO"},{"name":"Andrew Van Vurst","role":"Chief Operating Officer"},{"name":"Philip Trip Taylor","role":"Investor Relations (Gilmartin Group)"}],"products":["BioRetain","CryoTek","SteriTek","Neox","Clarix","VENDAJE","American Amnion"],"companies":[{"name":"BioStem Technologies, Inc.","ticker":"BSEM"}],"dollarAmounts":[{"amount":"$2.00 per share","context":"stock option exercise price"},{"amount":"$1 million","context":"aggregate purchase price for 500,000 shares exercised by CEO and COO"}]},"materialImpact":{"score":2,"reasoning":"CEO and COO exercised options and paid ~$1 million in cash to the company, signaling insider confidence and adding ~$1M capital. However, the dollar amount and 500,000-share exercise are modest for a small-cap and not market-moving."},"tickerRelevance":{"others":[],"primary":"BSEM"},"globalImportance":20,"audienceRelevance":20,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"insider option exercise ~$1M","insiderCashInBoost":true}},"event_type":"insider_transaction","event_type_secondary":["dilution"],"sentiment":"bullish","material_impact_score":2,"narrative":"BioStem Technologies' Chair and CEO Jason Matuszewski and COO Andrew Van Vurst each exercised options for 250,000 shares at $2.00 per share, paying approximately $1 million in aggregate cash to the company.\n\nBoth executives framed the exercises as a vote of confidence, with the capital earmarked to support sales coverage, hospital formulary expansion, and inventory for new accounts.\n\nOption exercises by insiders inject cash into the company but also add 500,000 shares of dilution; the modest size caps the market significance of the event.","key_figures":{"customDimensions":{"shares_exercised_each":250000,"shares_exercised_total":500000,"aggregate_purchase_price":"$1 million","exercise_price_per_share":"$2.00"}},"named_entities":{"people":[{"name":"Jason Matuszewski","role":"Chair and CEO"},{"name":"Andrew Van Vurst","role":"Chief Operating Officer"},{"name":"Philip Trip Taylor","role":"Investor Relations (Gilmartin Group)"}],"products":["BioRetain","CryoTek","SteriTek","Neox","Clarix","VENDAJE","American Amnion"],"companies":[{"name":"BioStem Technologies, Inc.","ticker":"BSEM"}],"dollarAmounts":[{"amount":"$2.00 per share","context":"stock option exercise price"},{"amount":"$1 million","context":"aggregate purchase price for 500,000 shares exercised by CEO and COO"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T11:00:15.993Z","global_importance":20,"audience_relevance":20,"importance_components":{"tickerTier":"micro-cap","eventGravity":"insider option exercise ~$1M","insiderCashInBoost":true}},"durationMs":6964,"modelName":"glm-5.3-flashx"}}